• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, July 3, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Immune discovery set to boost cancer therapies, study suggests

Bioengineer by Bioengineer
May 28, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Cancer therapies that use immune cells to trigger the body to attack tumours could be improved by a molecule that boosts their function.

Studies with mice have found the improved therapies produced a powerful anti-cancer immune response, which led to tumours shrinking.

Initial experiments show the molecule has similar effects on human cells and could boost the success of cancer therapies for people.

The molecule – called LL-37 – is produced naturally by the body in response to infections and helps to kill harmful bacteria and viruses.

Scientists at the University of Edinburgh found it also influences immune cells and boosts their function.

In particular, the molecule boosts the function of specific cells that are responsible for initiating targeted immune responses – called dendritic cells.

Dendritic cells have been used as cancer therapies because they can trigger other immune cells to recognise and attack tumours.

This approach typically involves taking a sample of the patients’ own cells and growing them in the lab under special conditions before infusing them back into the patient.

The process is expensive and has been hampered by difficulties with preparing sufficient numbers of dendritic cells that have the right characteristics for use as therapies.

Researchers at the University’s Centre for Inflammation Research found that adding LL-37 to dendritic cells while they are growing in the lab boosts yields of cells suitable for clinical use.

Treating mice with cells grown in this way helped to shrink tumours and, in some cases, led to complete clearance of the cancer.

Early tests suggest LL-37 has similar effects on human cells but further studies are needed, the researchers say.

The study, published in the journal Oncoimmunology, was funded by the Medical Research Council and the Royal Society.

Dr Emily Gwyer Findlay, of the University of Edinburgh’s Centre for Inflammation Research, said: “Our research has previously focused on the potential LL-37 has for fighting infections, but excitingly we now find that this substance, which the body makes naturally, could be used in new cancer treatments too.

“We hope that our discovery will create new opportunities by overcoming some of the current road-blocks to effective use of dendritic cell-based cancer therapies.”

###

Media Contact
Jen Middleton
[email protected]
http://dx.doi.org/10.1080/2162402X.2019.1608106

Tags: BiologycancerCell BiologyImmunology/Allergies/AsthmaMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Apelin-APLNR Pathway: Endothelial Roles in Health

July 2, 2026

Three Clinical Scholars Join Ludwig Institute for Cancer Research

July 2, 2026

Validating 18F-THK5351 for Imaging Astrogliosis

July 2, 2026

Next-Generation HIF-2α Inhibitor Demonstrates Potential in Translational Clinical Trial for Kidney Cancer

July 2, 2026
Please login to join discussion

POPULAR NEWS

  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • Saying Goodbye to PGY-6: Pediatric Fellowship Realities

    103 shares
    Share 41 Tweet 26
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15
  • KTU Researchers Explore Ultrasound’s Role in Enhancing Blood Flow Beyond Diagnostics

    53 shares
    Share 21 Tweet 13

About

BIOENGINEER.ORG

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Steatosis Drives Liver Metastasis Diversity in CRC

Unlocking the Mysteries of Alzheimer’s Disease

Pensoft Introduces New Peer-Reviewed Journal of Regeneration to Advance Restorative Biology Across Species

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 83 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.